ClinicalTrials.gg
RecruitingNCT05903235Updated Oct 22, 2026

Mixed Reality and Virtual Reality Technology With Mirror Therapy for Stroke Rehabilitation

An interventional study of Virtual Reality-based Mirror Therapy (VR+MT) and Mixed Reality-based Mirror Therapy (MR+MT) in Stroke, Cerebrovascular Disorders and Central Nervous System Diseases, sponsored by Chang Gung Memorial Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Chang Gung Memorial Hospital · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.
Updated Oct 22, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 88 studies in Stroke by Chang Gung Memorial Hospital — 13 open to participants now, 13 under way, none of them phase 3. Stroke · Chang Gung Memorial Hospital.

Planned enrollment
45th of 82
45 · median 55
Started
2024
with 2 others
No phase
71 of 88
13 open now
Primary completion
2027-07
later than 6 of 12 live
Registered
77th of 88
by date

Among the 88 studies in Stroke by Chang Gung Memorial Hospital, this one is the 45th largest by planned enrollment of the 82 interventional ones that give a count, is one of 3 that started in 2024, is one of 71 with no phase, reaches primary completion later than 6 of the 12 other live ones, and was the 77th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

13 of the 88 studies in Stroke by Chang Gung Memorial Hospital are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Stroke by Chang Gung Memorial Hospital, or all of them as a file.
02

Study summary

The specific study aims will be:

  1. To design and develop the hardware and software of the VR+MT and MR+MT systems.
  2. To test the feasibility of the VR+MT and MR+MT systems from the patients and to collect the feedback of users with respect to their experiences.
  3. To examine the treatment effects of VR+MT and MR+MT compared to the traditional MT (i.e., control group) in patients with stroke by conducting a randomized controlled trial.
  4. To identify who will be the possible good responders to VR+MT and MR+MT based on their baseline motor functions and mental imagery abilities.
Read the detailed description

Phase Ⅰ: Design and Development of the VR+MT and MR+MT Systems \& Feasibility Study

Sixteen patients with stroke will be recruited in this phase Ⅰ study. During the pilot testing, each stroke patient will use each of the VR+MT and MR+MT systems with the assistance of a researcher holding the occupational therapist certification. The order of the feasibility test of the 2 systems will be counterbalanced across the patients. At the end of the feasibility study of each system, the patients will be asked to complete the System Usability Scale, Virtual Reality Sickness Questionnaire, and a self-designed questionnaire to assess the user experience and perspective about these new systems and their view of its suitability for stroke patients.

Phase Ⅱ: Validation and Comparison of Clinical Treatment Efficacy

This three-arm, single-blind, randomized controlled trial will investigate the treatment effects among the 3 groups of VR+MT, MR+MT, and traditional MT. An estimated 45 patients with stroke will be recruited to participate in this phase Ⅱ study. Each participant will receive a total of 15 training sessions (40 minutes per session) within 5 weeks. Clinical outcome measures will be conducted at baseline, at immediately after treatment, and at 1 month follow-up after treatment.

03

Conditions studied

  • Stroke
  • Cerebrovascular Disorders
  • Central Nervous System Diseases

Keywords

  • digital rehabilitation
  • mixed reality
  • virtual reality
  • cerebrovascular accident
  • mirror visual feedback
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Phase Ⅰ: Design and Development of the VR+MT and MR+MT Systems \& Feasibility Study

Inclusion Criteria:

  • diagnosed with unilateral stroke
  • age of 20 to 80 years
  • a baseline Fugl-Meyer Assessment of the Upper Extremity score of 20 to 60
  • able to follow the study instructions and provide the feedback of user experiences verbally

Exclusion Criteria:

  • diagnosed with global or receptive aphasia
  • the presence of severe neglect
  • the existence of major medical problems or comorbidities that could interfere with upper-limb usage and pain, or disrupt visual or auditory perception

Phase Ⅱ: Validation and Comparison of Clinical Treatment Efficacy

Inclusion Criteria:

  • diagnosed with unilateral stroke
  • more than 6 months after stroke onset
  • age of 20 to 80 years
  • a baseline Fugl-Meyer Assessment of the Upper Extremity score of 20 to 60
  • able to follow the study instructions
  • capable of participating in the assessment process and treatment program

Exclusion Criteria:

  • diagnosed with global or receptive aphasia
  • the presence of severe neglect
  • the existence of major medical problems or comorbidities that could interfere with upper-limb usage and pain, or disrupt visual or auditory perception
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Virtual Reality-based Mirror Therapy (VR+MT)

    In each therapy session, the patients will execute 2 upper-limb functional tasks, starting with easy then more complex tasks.

    Behavioral: Virtual Reality-based Mirror Therapy (VR+MT)

  • Experimental
    Mixed Reality-based Mirror Therapy (MR+MT)

    The patients will execute 2 upper-limb functional tasks in each session.

    Behavioral: Mixed Reality-based Mirror Therapy (MR+MT)

  • Active comparator
    Traditional Mirror Therapy (MT)

    The patients will execute 2 to 3 categories of activities per training session: (1) active range of motion exercises, (2) reaching movement or object manipulation, and (3) upper-limb functional tasks.

    Behavioral: Traditional Mirror Therapy (MT)

Interventions

  • BehavioralVirtual Reality-based Mirror Therapy (VR+MT)

    In this VR+MT group, the patients will be instructed to perform the unilateral movements of the non-affected upper limb simultaneously while observing the animated hand as mirroring reflection of the affected hand within the immersive environment, which presented on the goggle via the VR+MT system.

  • BehavioralMixed Reality-based Mirror Therapy (MR+MT)

    In the MR+MT group, the patients will be instructed to perform the unilateral movements of the non-affected upper limb concurrently meanwhile watching the real-time mirroring image reflection of the non-affected upper limb's movements of the patients captured, transformed, and superimposed on the affected upper limb, which projected to the screen from the front side via the MR+MT system.

  • BehavioralTraditional Mirror Therapy (MT)

    In the traditional MT group, patients will be instructed to perform the unilateral movements of the non-affected upper limb at the same time while watching the mirror of a mirror box placed in front of the patient's midsagittal plane, in which the illusory reflection of the non-affected upper limb appears as if it were the another affected upper limb.

06

What researchers measure

Primary outcomes

  1. Change scores of Fugl-Meyer Assessment of the Upper Extremity

    The Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) is a measure with sound psychometric properties to evaluate upper-limb hemiparesis of patients following stroke. The total, proximal and distal scores of the FMA-UE range from 0 to 66, from 0 to 42, and from 0 to 24, respectively; a higher score indicates better upper-limb motor function.

    Time frame: baseline, 5 weeks, 9 weeks

  2. Change scores of Nottingham Extended Activities of Daily Living scale

    The Nottingham Extended Activities of Daily Living scale is an ease-of-use measure with sound reliability and validity to assess independence of more complex daily function. Each item scores ranged from 0 (no/unable) to 3 (on my own/able) with a total score range of 0 to 66. A higher score indicates greater independence of instrumental activities of daily living.

    Time frame: baseline, 5 weeks, 9 weeks

Secondary outcomes

  1. Change scores of grip strengths

    The Jamar® Plus+ Digital Hand Dynamometer has been designed similarly to the reliable and validated Jamar Hydraulic Hand Dynamometer to measure the grip strength. The grip strengths of both hands were alternatively measured in kilograms (kg) by adopting the average of three measurements.

    Time frame: baseline, 5 weeks, 9 weeks

  2. Change scores of lateral pinch strengths

    The Jamar® Plus+ Digital Pinch Gauge has been developed and widely used with the advantages of an easy-to-read digital readout and being capable of storing data. The lateral pinch strengths of both hands will be alternatively measured in kilograms (kg) by adopting the average of three measurements.

    Time frame: baseline, 5 weeks, 9 weeks

  3. Change scores of palmar pinch strengths

    The Jamar® Plus+ Digital Pinch Gauge has been developed and widely used with the advantages of an easy-to-read digital readout and being capable of storing data. The palmar pinch strengths of both hands will be alternatively measured in kilograms (kg) by adopting the average of three measurements.

    Time frame: baseline, 5 weeks, 9 weeks

  4. Change scores of Box and Block Test

    The Box and Block Test (BBT) is a tool with sound reliability and validity to evaluate hand dexterity. The number of cubes moved represents the BBT score, with a higher score indicating better gross dexterity.

    Time frame: baseline, 5 weeks, 9 weeks

  5. Change scores of Revised Nottingham Sensory Assessment

    The Revised Nottingham Sensory Assessment is a standardized measure with good reliability to evaluate sensory function of patients following stroke. The scores of the tactile sensation, proprioception, and stereognosis subscales range from 0 to 108, from 0 to 21, and from 0 to 22, respectively; a higher score indicates better somatosensory function.

    Time frame: baseline, 5 weeks, 9 weeks

  6. Change scores of Chedoke Arm and Hand Activity Inventory

    The Chedoke Arm and Hand Activity Inventory is a reliable and validated measure to evaluate the independence of patients following stroke to perform activities of daily living with an affected upper limb. Each task scores ranged from 1 (total assist) to 7 (complete independence) with a total score range of 13 to 91. A higher score indicates greater recovery of arm and hand function.

    Time frame: baseline, 5 weeks, 9 weeks

  7. Change scores of the health state of EQ-5D-5L

    The questionnaire of EQ-5D-5L comprises 5 dimensions, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, and uses a 5-point Likert scale scored from 1 (no problem) to 5 (unable to/extreme problems); whereas, the numerical description of 5-dimension questionnaire represents the health state.

    Time frame: baseline, 5 weeks, 9 weeks

  8. Change scores of the visual analogue scale of EQ-5D-5L

    The visual analogue scale of EQ-5D-5L score will be scored from 0 to 100. A higher score indicates better overall current health.

    Time frame: baseline, 5 weeks, 9 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jul 2027, 40 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 40 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Jul 2026 → Jul 2027 and completion Jul 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2023
First posted
Jun 15, 2023
StartActual
Mar 13, 2024
Primary completionEst.
Jul 31, 2027was Jul 2026
CompletionEst.
Jul 31, 2027was Jul 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 31, 2026→Jul 31, 2027
Oct 22, 2026
Study completion
Jul 31, 2026→Jul 31, 2027
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Primary completion Jul 31, 2026→Jul 31, 2027
    Study completion Jul 31, 2026→Jul 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05903235
Responsible party
Sponsor
First posted
Jun 15, 2023
Start date
Mar 13, 2024
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Yu-Wei Hsieh, PhD
Contact
ywhsieh@mail.cgu.edu.tw
+886-3-2118800 ext. 3820
Yu-Wei Hsieh, PhD
principal investigator · Department of Occupational Therapy, College of Medicine, Chang Gung University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion